Infections are a leading cause of morbidity and mortality in children under the age of 5 years worldwide [1] . Although early and effective antimicrobial administration represents an important therapy leading to decreased patient morbidity and mortality [2] [3] [4] , widespread antimicrobial use may result in the unintended emergence of antimicrobial-resistant bacteria [5] [6] [7] [8] . Antimicrobial resistance in turn leads to increased patient morbidity and mortality as well as rising healthcare expenditures [6, 9] . Antimicrobial resistance has been recognized as an increasingly serious threat to global public health that requires action across all government sectors and societies [10] .
In an effort to counter antimicrobial resistance, accurate early identification of causative organisms allows clinicians to quickly ensure effective antimicrobial treatment, optimize therapy, and/ or decrease patient exposure to unnecessary broad-spectrum antibiotics [5, [11] [12] [13] [14] [15] [16] [17] [18] . Matrix-assisted laser desorption and ionization time-of-flight (MALDI-TOF) is a rapid identification technology that enables very reliable identification of organisms approximately 1 to 1.6 days earlier than routine methods [11-14, 16, 18] . This technology uses mass spectrometry to analyze the spectral fingerprints unique to genus, species, and subspecies of an organism that are subsequently compared with commercial databases to enable identification [19] .
Antimicrobial stewardship is increasingly recognized as essential for optimal antimicrobial administration in children [20] [21] [22] [23] [24] [25] [26] . In adults, the combination of rapid organism identification technologies and antimicrobial stewardship programs (ASPs) have facilitated more rapid de-escalation of antibiotic therapy compared with rapid organism identification alone [27] . Antimicrobial stewardship pharmacists were able to adjust and optimize therapy, even before susceptibilities were available, by incorporating the real-time isolate results to make empiric recommendations [11, 12, 15, 17] . However, comparable studies in the pediatric population are lacking. The primary objective of this study is to assess the impact of MALDI-TOF technology and an ASP on the time to effective and optimal antimicrobial therapy in hospitalized children with blood stream infections (BSIs), compared with standard methods.
METHODS
This is a single-center retrospective cohort study comparing a total of 221 bacteremia/fungemia episodes at a tertiary center postimplementation of MALDI-TOF and ASP to a historical preintervention control group. Our institution implemented MALDI-TOF technology in September of 2013, and an ASP was initiated in October of 2013 ( Figure 1 ). The preintervention study period was designated between October 2009 and July 2010, whereas the postintervention period was matched to the same 10 calendar months (October-July) between 2013 and 2014 ( Figure 1 ).
The inclusion criteria were as follows: patients aged between 0 and 18 years admitted to an inpatient ward at British Columbia Children's Hospital (BCCH), with a positive blood-stream culture for bacteria or yeast that was treated with 1 or more antimicrobial agents. Patients were excluded if they had a positive blood culture that was identified before BCCH admission, if they were discharged between the time of obtaining the blood culture and time of culture positivity, or if they had a blood culture that was identified as a contaminant in the medical records by the treating physician ( Figure 2 ). Each episode of BSI was considered as a separate event, rather than as separate patient events. Therefore, individual patients could be included in the study more than once if they had a separate BSI(s), even while on treatment for the first BSI, if the organisms were different. Patients were not restricted on the basis of time periods between BSIs. This study was approved by the institutional research ethics review board.
Each patient chart was reviewed by 2 or more independent reviewers with >10% overlap between reviewed charts to ensure consistency. Data were collected in REDCap using a standardized form. Outcomes assessed included time to optimal and effective therapy, pathogen identification, 30-day all-cause mortality, hospital and pediatric intensive care unit length of stay following blood culture positivity, time to microbiological clearance, recurrent bacteremia within 30 days of discontinuation of antimicrobial therapy, and 30-day readmission rate for recurrent bacteremia with the same organism (Figure 2 ). In the postintervention period, we also examined the type of ASP interventions suggested by the team and intervention acceptance rate by the treating clinicians.
An assessment of whether antimicrobial therapy was optimal was done independently by 2 members of the study team, an antimicrobial stewardship pharmacist, and an infectious diseases specialist, with at least 1 member blinded to the patient's study group. A third party member was available to adjudicate unresolved disagreements. Time to effective therapy was defined as time from blood culture collection to time of administration of first antimicrobial with known susceptibility [11] . Time to optimal therapy was defined as time from blood culture collection to time of administration of first antimicrobial with narrowest effective spectrum based on susceptibility and cessation of antimicrobials with unnecessary coverage, taking into account relevant patient-specific factors such as coexistent infections, allergies, or intolerances [11] .
Preintervention Cohort
In the preintervention period, blood cultures were collected into Bactec Ped-Plus/F, Aerobic/F, and/or Lytic 10 Anaerobic/F bottles (Becton Dickinson, Mississauga, Ontario). Volume of blood draw followed institutional protocol derived from Clinical Laboratory Standards Institute (CLSI) guidelines [28] . Inoculated bottles were transported to the laboratory and loaded onto the Bactec FX instrument within 20 minutes of collection. The contents of all bottles that were positive were Gram stained and subcultured. Outside of the regular microbiology laboratory working hours of 7:00 am to 11:00 pm, the microbiology technologist was called back immediately, without time delay to processing of samples, for positive bottles via cell phone using the Sentinel automatic system (Becton Dickinson). During the control preintervention period, Gram stain results were entered into the laboratory information system, transmitted to the ward via fax, and then also transmitted via telephone. Bottles were subcultured to agar plates based on Gram morphology, and isolates were identified by standard methods once sufficient growth was obtained [29] . Susceptibilities were performed using a Becton Dickinson Phoenix, E-test strips (bioMérieux, Saint-Laurent, Quebec), and Kirby Bauer [29] , using CLSI and European Committee on Antimicrobial Susceptibility Testing breakpoints. During this period, there was no ASP and no restrictions on use of any antimicrobials at our institution.
Prospective Cohort
In the postintervention study period, collection and susceptibilities were performed identically to the method outlined above [29] . In addition, an aliquot from each positive blood culture was also extracted using the Sepsityper kit (Bruker Daltonics, Milton, Ontario), and immediately processed and identified in duplicate on a Bruker Daltonics Microflex LT instrument, using BioTyper software version 3.1. Sepsityper was performed on all shifts and samples were run throughout the day and night (ie, were not batched). Identified organisms were compared with the Gram stain results, entered into the laboratory information system, then transmitted via telephone to the ward. During this period, we also examined the number and type of ASP interventions and intervention acceptance rate by the treating clinicians.
Validation of Matrix-Assisted Laser Desorption and Ionization Time-of-Flight
The MALDI-TOF system had been validated in a multicenter study of 2200 isolates [30] . A validation period occurred at our center from May 2011 to June 2011 in "evaluation period one" (Figure 1 ). Based on the validation study, identifications were considered valid if the score was >2.000 and there was a 10% gap to the next highest species score. Scores of >1.700 but less than 2 were considered valid genus-level identifications. Specimens that could not be identified directly by MALDI-TOF were reported by Gram stain, and isolates from the agar plates were identified by standard methods as per the control period. Bottles identified as Streptococcus pneumoniae were reported as "Streptococcus pneumoniae or mitis -identification to follow" and tested by bile solubility and optochin susceptibility the next day.
Antimicrobial Stewardship Program
The British Columbia Children's Hospital Antimicrobial Stewardship Program implemented prospective audit and feedback in September 2013. Audit and feedback was conducted Monday to Friday from 8:00 am to 4:00 pm by an ASP clinical pharmacy specialist with daily support from the infectious diseases team, clinical microbiologists, and infection control nurses. During the intervention period, the ASP pharmacist checked all cultures and susceptibility results in the morning via the electronic medical record. In addition, the ASP pharmacist received a "Significant Findings" report from microbiology each afternoon with a listing of positive blood cultures. Blood stream infection results reported outside the hours of ASP operation were reviewed the following working day. The prospective audit and feedback entailed verbal communication with the treating team and documentation in the patient record.
Sample Size Calculation
A sample size calculation was performed using an alpha of 0.05 and a power of 0.80. A recent study on the impact of using MALDI-TOF with antimicrobial stewardship intervention demonstrated mean differences pre-and postintervention of approximately 10 hours to effective therapy and approximately 43 hours in time to optimal therapy [11] . Based on this study with an estimated preintervention time to effective therapy of 30 hours, a 10-hour difference in the postintervention group of 20 hours, and a standard deviation of 20 hours, we calculated a required sample size of 63 bacteremias in each group. To account for the use of a nonparametric test, we increased the sample size to 100 bacteremias per group.
Statistical Analysis
REDCap data were extracted into an Excel spreadsheet and analyzed using SPSS software version 20.0 (SPSS Inc., Chicago, Illinois). Baseline demographic data were analyzed using descriptive statistics. For the 2 primary outcomes, a Mann-Whitney U test was used (1) for median time to effective and optimal therapy and (2) for all secondary outcomes measuring time. Secondary outcomes with categorical data were analyzed by 2-tailed Student's t test, and dichotomous data were analyzed using Fisher's exact test or χ 2 test. A stratified analysis was performed for patients with Grampositive organisms, Gram-negative organisms, exclusion of yeasts, treatment not using the neonatal intensive care unit (NICU) coagulase-negative Staphylococci protocol, and for Pseudomonas aeruginosa and multidrug-resistant Gramnegative bacilli.
RESULTS
Our study included 100 episodes of BSIs in the preintervention group and 121 in the postintervention group (Figure 2) . Baseline demographics were similar between the 2 groups; however, the preintervention group had more immunosuppressed patients and required more infectious disease consultations ( Table 1 ). The distribution of organisms was similar in both groups ( Table 2 ). The median length of stay was not significant different between the 2 study groups.
Of the initial positive blood cultures, 67% were reported successfully by MALDI within 2 hours of culture positivity. Of the remaining cultures, 11% did not identify due to difficulty accurately separating S pneumoniae from Viridans Group Streptococci. Another 11% did not initially give a clear differentiation between Staphylococcus aureus and other staphylococci, particularly Staphylococcus epidermidis. The latter was resolved by MALDI once isolates appeared on the subplates.
The use of MALDI-TOF and ASP resulted in a significant reduction in time to optimal therapy from 77.0 to 54.2 hours (P < .001) ( Table 3 ). There was a strong, although not statistically significant, trend towards reduced time to effective therapy (2.6 vs 1.6 hours, P = .058). The median time from blood culture collection to organism identification was significantly reduced (43.7 vs 18.8 hours, P < .001) ( Table 3 ). There were no statistically significant differences in other clinical outcomes (Table 3) .
Subgroup analyses of patients with Gram-negative bacteremia demonstrated a significant reduction in both time to effective therapy (2.0 vs 0.7 hours, P = .043) and time to optimal therapy (146.8 vs 48.0 hours, P < .001) ( Table 4) . Subgroup analysis of patients with multidrug resistant (MDR) Gram-negative bacilli demonstrated significantly reduced time to organism identification (41.3 vs 16.7 hours, P = .002) and time to optimal therapy (149.5 vs 16.0 hours, P = .002) ( Table 4) .
The ASP audited a total of 106 bacteremia/fungemia episodes (87% of total cases in the postintervention group) and made 1 or more recommendations for 73 of the episodes (68.9% of audited cases) and a cumulative total of 140 recommendations (Table 5) . A total of 110 (78.6%) recommendations were accepted. The most common ASP recommendations were as follows: discontinuation of antimicrobials (n = 45), tailoring therapy to culture and susceptibility (n = 38), and optimization of dose (n = 20) (Table 5 ). In total, ASP made 15 recommendations to broaden therapy and 36 recommendations to narrow therapy (Table 5 ).
DISCUSSION
Our study included 221 bacteremia/fungemia episodes and revealed that the use of MALDI-TOF and ASP resulted in significantly decreased time to optimal therapy in pediatric inpatients. These findings are significant because efforts to limit antimicrobial resistance rely on effective and optimal use of antibiotics in addition to robust antimicrobial stewardship [5, 6] . Evidence suggests that approximately 45%-70% of hospitalized pediatric inpatients are treated with 1 or more antimicrobial(s) during admission [20, 23, 24, 31] . Variability in prescribing practices exists even for common childhood illnesses [24, 32] . In the pediatric population, ASP has previously demonstrated success in stabilizing antimicrobial resistance patterns, reducing antimicrobial use, and improving quality of care for hospitalized patients [20] .
Our study of 221 bacteremia/fungemia episodes represents the largest study examining the impact of a combined use of MALDI-TOF and ASP in the pediatric population to date. In addition, our study reviewed clinical data for all identified patients and included patients with polymicrobial infections as well as fungal infections. Although both cohorts were similar, the preintervention group included more immunosuppressed patients and also had more consultations from infectious disease specialists, suggesting that the preintervention population may have been more medically complex (Table 1) . Demographics, with respect to ward of admission at time of BSI, were similar, with slightly more patients from the NICU in the postintervention group. The cause of increased length of stay in the postintervention group is difficult to interpret because this is potentially confounded by many variables including discharge planning, home care, medical needs unrelated to BSI, and other medical and social issues.
Our data demonstrate that the combination of MALDI-TOF and an ASP significantly reduces time to optimal therapy in pediatric inpatients (Table 3 ). This reduction is consistent with previous trends reported in adult populations [11, 13, 14] . Although time to effective therapy was not statistically significant between the groups, the 1-hour reduction (2.6 vs 1.6 hours) could be clinically important given that each hour effective antimicrobial therapy can be initiated earlier may yield a decrease in mortality in sepsis [3, 4] . Our ASP also recommended broadening therapy for 15 cases of BSIs to ensure effectiveness. This may have been associated with the significantly decreased time to effective therapy in the subgroup analysis of Gram-negative bacteremias.Although not statistically significant, our study also demonstrates a strong trend towards reduced time from blood culture collection to full reporting of susceptibilities by almost 3 days. Rapid identification via the MALDI-TOF allows our medical microbiology team to initiate in vitro testing for susceptibilities more quickly in some cases, which may lead to earlier initiation of optimal therapy, as reported above. Over two thirds of the bacteremia episodes received ASP interventions, demonstrating the important partnership between innovative technology and ASPs. The specific recommendations made by our ASP team highlight the uniqueness of pediatric populations (Table 4) . Whereas in adult populations, Readmission within 30 days (%) 22 ( early intravenous to oral stepdown is encouraged, this is not yet the standard approach to most bacteremia treatment in pediatric patients, and thus it is not a common stewardship intervention [33, 34] . There were also a number of episodes requiring more than 1 ASP intervention demonstrating the utility of timely and continued feedback with the clinical care teams to optimize empiric and tailored regimens. Ongoing collaboration with care teams via prospective audit and feedback is necessary and effective.The overall acceptance rate of ASP interventions was 78.6%, which is similar to recently reported data in adult literature specific to bacteremia and fungemia treatment in partnership with the use of MALDI-TOF [11, 13] . However, this rate is lower than a previously published pediatric study where the overall acceptance of agreed-upon APS recommendations, not specific to bacteremia/fungemia therapy, was 92% [35] . Comparison of acceptance rates is challenging because classification of acceptance is not standardized and is therefore not a consistent method by which to compare effectiveness of audit and feedback programs. The acceptance rate of ASP interventions at our institution varied significantly depending on the clinical service ( Table 5 ). The NICU had the lowest intervention acceptance rate, perhaps partially due to a department-specific coagulase-negative staphylococcal bacteremia treatment protocol that was in use. Prospective audit and feedback may serve to ensure optimal use of antimicrobials at our center by bridging the gap that may exist between prescribing practices and institutional antimicrobial guidelines. Strengths of this study include the detailed chart review for every study patient by at least 2 investigators for improved accuracy. Adjudication of effective and optimal antimicrobial therapy was undertaken by 2 investigators for each case, 1 of whom was blinded. One hundred percent agreement of effective and optimal therapy was obtained for all cases between the 2 adjudicators. We also included a wide range of positive blood cultures including a wide range of bacterial, fungal, and polymicrobial isolates. This provided a more comprehensive examination into the impact of MALDI-TOF and an ASP. We collected detailed information regarding ASP interventions to characterize interventions to better characterize the partnership between ASP and technology in pediatric bacteremias.
Our study has several limitations. Although we met our target sample size, our study population is from a single center and results may be difficult to extrapolate to other centers with differing ASP services. The retrospective nature of our study is subject to the biases of historical review, restricting our ability to clearly delineate the rationale for apparent ineffective or suboptimal antimicrobial therapy. Our pre-and postintervention groups were over 3 years apart because there were intermittent trials of using the MALDI between 2010 and 2012. Therefore, we are unable to account for changes and evolution of institutional practices and medical knowledge that may have occurred in the period between the pre-and postintervention groups, such as the increasing pressures for earlier discharges and gradual understanding of the importance of using antimicrobials appropriately. Although there were 2 validation periods in which the MALDI was running without an ASP (July-August 2012 and April-August 2013), the MALDI was not fully operationalized at that time, and in some cases there were delays in generating results. These operational delays would very likely confound the data of a MALDI-only period, and we are therefore unable generate a representative data set for a third, MALDI-only, intervention group (Figure 1) .
Although our study used the quasi-experimental design of pre-and postanalysis, there are strengths and limitations inherent to this design type. One of the strengths of this design is the intuitive interpretability of the results and simplicity of Abbreviations: ASP, antimicrobial stewardship program; BSI, blood stream infection; ID, infectious diseases; IV, intravenous; PO, oral. *Of the total 121 episodes of bacteremias/fungemias, 106 (87%) were audited: four were not audited because they were oncology patients, and, at the time of the BSIs, the ASP program had not yet expanded to include oncology patients. The remainder are attributed to days when ASP was not auditing.
design structure [36] . Some of the limitations include difficulty in adjusting for confounders (as described above) and difficulty in detecting changes in trends or slopes [36] . Although a time series analysis has the advantage of estimating a stronger correlation between interventions and outcomes over time, controlling for confounding trends in data, and increased ability to evaluate the consequences of the intervention (intended or otherwise) [36] [37] , our study was not powered for sufficient observation points to make complex correlation structures.
Further limitations include that this study focused only on patients with BSIs and therefore likely underestimates the full impact of MALDI-TOF and ASP on other infections, such as urinary tract or CSF infections. In addition, our institution currently does not have an ASP that operates 24 hours a day, 7 days a week. This gap in ASP coverage potentially reduces the beneficial outcomes of a combined MALDI-TOF and ASP approach.
CONCLUSIONS
In conclusion, MALDI-TOF in partnership with an ASP allows faster optimization of antimicrobial therapy for pediatric patients with positive blood cultures and may improve time to effective therapy. The clinical impact of these interventions is yet to be determined. 
